1. Mean Responses on PGI-Improvement Primary Endpoint at Week 12
Very much better 1
Much better 2
***
***
***
***
A little better 3
No change 4 2 4 8 12
A little worse 5
Week of Study
Much worse 6
Duloxetine
Placebo
Very much worse 7
*** P<0.001 vs placebo
PGI=Patient Global Impression.
At week 12 57% of duloxetine patients who had a PGI-I score ≤2, which was significantly more than patients in the placebo group.

2. LOCF Mean Change from Baseline to Endpoint in MFI Subscale Scores
17.0
17.1
15.4
15.3
13.2
12.9
13.7
13.6
12.4
12.5
Improvement **
*** ** * **
Duloxetine
Placebo
General Fatigue
Physical Fatigue
Mental Fatigue
Reduced Activity
Reduced Motivation
* P≤ 0.05; ** P≤ 0.01; *** P≤ 0.001
LOCF= last observation carried forward; MFI= Multidimensional Fatigue Inventory.
There were no significant between-treatment differences at baseline.

3. Beck Depression Inventory Beck Anxiety Inventory
LOCF Mean Change from Baseline to Endpoint in Beck Depression and Anxiety Inventories
Beck Depression Inventory
Beck Anxiety Inventory **
15.8
16.3
12.4
13.3
Duloxetine
Placebo
Improvement
Baseline:
** P<0.01 vs placebo
LOCF= last observation carried forward.